Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant

Current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased ov...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Altavilla, Amelia, Iacovelli, Roberto, Procopio, Giuseppe, Alesini, Daniele, Risi, Emanuela, Campennì, Giuseppe Maria, Palazzo, Antonella, Cortesi, Enrico
Format: Artigo
Sprache:Inglês
Veröffentlicht: Landes Bioscience 2012
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461806/
https://ncbi.nlm.nih.gov/pubmed/22825325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.21188
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge